Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05625971
Other study ID # AAAU0686
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 14, 2022
Est. completion date September 2024

Study information

Verified date December 2023
Source Columbia University
Contact Research Nurse Navigator
Phone 212-342-5162
Email cancerclinicaltrials@cumc.columbia.edu
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to investigate the sensitivity and accuracy of non-invasive MRD assessment using liquid biopsy (blood draw) and functional imaging (whole body MRI) in participants with new diagnosed and previously treated multiple myeloma. The long-term goal of this study is to investigate whether non-invasive methods for MRD assessment can replace bone marrow aspiration and biopsy in a substantial percentage of participants with multiple myeloma.


Description:

There is an unmet clinical need for an easier, non-invasive, and reliable method to perform MRD assessments that can be used in clinical trials and routine practice. The two non-invasive modalities that are most promising for MRD assessment are liquid biopsy to detect circulating tumor cells (CTCs) and functional imaging to detect focal myeloma lesions. However, there are no prospective data on the sensitivity and specificity of non-invasive MRD assessment with respect to the gold standard of bone marrow sampling.


Recruitment information / eligibility

Status Recruiting
Enrollment 88
Est. completion date September 2024
Est. primary completion date September 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adults age =18 years - Patients with newly diagnosed multiple myeloma - Patients with previously treated multiple myeloma with a maximum of two prior lines of therapy - Expected life expectancy of greater than one year and intention to start a new line of treatment Exclusion Criteria: - Patients without cognitive capacity to give informed consent for participation - Patients with contraindications to MRI, which include the following: - Claustrophobia, which, at investigator's discretion, would prohibit patient from undergoing whole body diffusion-weighted magnetic resonance imaging (WB-DWI) - Pacemaker - Metallic implants, which would prohibit patient from undergoing MRI All subjects will be screened for any contraindication to MRI as per their guidelines at the time of patient enrollment. - Patients must not receive granulocyte colony stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) injection within 1 week prior to WB-DWI. - Patients must not have been initiated on treatment prior to baseline disease assessment by bone marrow aspiration/biopsy and/or WB-DWI Up to 160 mg of dexamethasone (or equivalent) and/or 1 dose of bortezomib (+/- Cyclophosphamide-Dexamethasone) is allowed prior to disease assessment by bone marrow aspiration and WB-DWI.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
MRD Assessment
MRD assessment includes liquid biopsy and functional imaging. Liquid biopsy will be performed by the Adaptive ClonoSEQ® assay in peripheral blood. Functional imaging will be performed by whole body diffusion-weighted magnetic resonance imaging (WB-DWI).

Locations

Country Name City State
United States New York Presbyterian Hospital/Columbia University Irving Medical Center New York New York

Sponsors (2)

Lead Sponsor Collaborator
Rajshekhar Chakraborty, MD Hope Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Sensitivity of non-invasive MRD assessment MRD assessment includes liquid biopsy and functional imaging. 6 months
Primary Specificity of non-invasive MRD assessment MRD assessment includes liquid biopsy and functional imaging. 6 months
Secondary Sensitivity of two MRD-testing algorithms Combining liquid biopsy, functional imaging, and bone marrow sampling against the reference of bone marrow sampling in patients 6 months
Secondary Specificity of two MRD-testing algorithms Combining liquid biopsy, functional imaging, and bone marrow sampling against the reference of bone marrow sampling in patients 6 months
Secondary Progression Free Survival The progression-free survival (PFS) will be calculated of patients who are MRD-positive and MRD-negative on each modality (liquid biopsy, functional imaging, and bone marrow sampling) 2 years
Secondary Overall Survival The overall survival (OS) will be calculated of patients who are MRD-positive and MRD-negative on each modality (liquid biopsy, functional imaging, and bone marrow sampling) 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT03832127 - Evaluation of PET 18F-Fludarabine for the Initial Assessment and End-treatment of Symptomatic Multiple Myeloma Patients Phase 1
Completed NCT01413178 - A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma Phase 3
Recruiting NCT03641456 - VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma Phase 2
Completed NCT03135925 - Feasibility of Pre Transplant Exercise (Pre-habilitation) for Multiple Myeloma Patients Awaiting Autologous Stem Cell Transplantation N/A
Terminated NCT02907073 - Positron Emission Tomography (PET) Imaging Studies With NIS Reporter Phase 1/Phase 2
Withdrawn NCT02114502 - Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma Phase 2
Completed NCT00794261 - Stem Cell Mobilization With Pegfilgrastim in Lymphoma and Myeloma Phase 2
Completed NCT01700608 - Prospective Observational Study on Plerixafor After Chemotherapy N/A
Completed NCT00800839 - Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide Phase 2
Completed NCT00606437 - Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants Phase 1
Recruiting NCT05528887 - Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies Phase 1
Active, not recruiting NCT02931942 - Changing Over Time of Ascorbic Acid After Chemotherapy
Active, not recruiting NCT05889221 - Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma N/A
Recruiting NCT03836690 - Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation Phase 1
Active, not recruiting NCT02542657 - Ixazomib With Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients With Multiple Myeloma Phase 1/Phase 2
Completed NCT01279694 - Trial of Carfilzomib Plus Melphalan and Prednisone in Elderly Untreated Patients With Multiple Myeloma (CARMYSAP) Phase 1/Phase 2
Completed NCT01191060 - Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years Phase 3
Terminated NCT00983346 - Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients Phase 2
Completed NCT00476294 - Long-Term Follow Up Study for AMD3100 Patients N/A
Completed NCT00344422 - Vincristine, DOXIL (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Phase 3